RBC Capital analyst Frank Morgan maintained a Hold rating on Fresenius Medical Care (NYSE:FMS) Corp. on Thursday, setting a price target of $42, which is approximately 6.90% above the present share price of $39.29.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
Top Stock Reports for PayPal, IBM & Fresenius Medical
Today, on International Nurses Day, Fresenius Medical Care, the world’s leading provider of dialysis products and services, is celebrating the extraordinary contribution that its nurses make to the organization and wider community – every day, and particularly in the face of our current global health challenge.
More than 1,000 employees have already rejoined the company to provide support during the COVID-19 pandemic.
European shares opened little changed on Wednesday as a batch of mixed earnings reports and simmering U.S.-China tensions added to doubts about a swift economic recovery even as many countries eased lockdown measures. The pan-European STOXX 600 index was flat as losses in oil and gas sector, following a recent surge, offset gains in healthcare shares. The global mood also remained fragile as U.S. President Donald Trump again took aim at China, urging it to be transparent about the origins of the novel coronavirus outbreak.
Fresenius Medical Care (FMC) on Wednesday said it was working with other dialysis providers to provide care in isolation for people with kidney problems in the United States who are or may be infected with coronavirus. FMC, the world's largest kidney dialysis provider, said it was collaborating with DaVita Inc., U.S. Renal Care, American Renal Associates, Satellite Healthcare and others on making a national contingency plan to ensure patients who need dialysis can continue to receive care by creating isolation capacity that other providers can use. "The companies are focused on ensuring there are enough nurses, social workers, dietitians, care technicians and available space to treat all dialysis patients, including those who are or may be infected with COVID-19, in a way that does not unnecessarily expose the hundreds of thousands of other patients who entrust them with their care," FMC said.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Fresenius Medical Care Holdings, Inc. Frankfurt am Main, April 17, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius Medical Care Holdings, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Healthcare companies worldwide have benefited from subsidies and increased demand as a result of the coronavirus crisis, but they have also faced new costs, including protective gear. Fresenius' first-quarter net income was 465 million euros ($503.97 million), above analysts' average forecast of 421.8 million euros, a Refinitiv poll found. "It is, however, too early to say with any certainty what impact COVID-19 will have on the company's full business year," Chief Executive Stephan Sturm said in a statement.
Image source: The Motley Fool. Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)Q1 2020 Earnings CallMay 6, 2020, 9:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by.
Fresenius Medical Care, the world’s leading provider of dialysis products and services, has today announced the international and digital expansion of its highly successful Asia Pacific-wide Corporate Social Responsibility (CSR) initiative, The Kidney Kid superhero. This colorful character takes children on a series of adventures to learn more about their ‘super organ’ kidneys and how to keep them healthy. The expansion of this initiative comes on World Kidney Day, which in 2020, is calling on everyone to advocate for concrete measures in every country to promote and advance kidney disease prevention.
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius Medical Care AG & Co. KGaA and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
The two companies and other organizations are committed to providing dialysis while limiting exposure.
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. By comparison...
With a growing incidence of chronic kidney diseases and end-stage renal failure in the United States, CVS Health's (CVS) new partnerships seem to be strategic.
Is Fresenius Medical Care AG & Co. KGaA (ETR:FME) a good dividend stock? How can we tell? Dividend paying companies...
Fresenius Medical's (FMS) first-quarter earnings benefit from strong segmental performance.